Dr. Lal Path Labs Acquires 70% Stake in SN Gene for ₹168 Cr + Earn-out
Dr. Lal Path Labs will acquire 70% of SN Genelab Private Limited for up to ₹168 Crores plus a ₹31.5 Crores earn-out. The acquisition aims to strengthen genomics expertise and expand diagnostic services. SN Gene reported FY26 revenue of ₹57.96 Crores. The deal is expected to close by November 30, 2026.
The acquisition of a 70% stake in SN Genelab, a genomics diagnostics company, is a strategic move that could enhance Dr. Lal Path Labs' service offerings and market position in a growing segment. The financial outlay is significant but within the company's capacity.
The acquisition is positive as it aims to strengthen the company's expertise in genomics and broaden its portfolio of advanced diagnostic services, which is expected to drive future growth.
Dr. Lal Path Labs Limited announced today, September 24, 2026, that its Board of Directors has approved the acquisition of a 70% stake in SN Genelab Private Limited ("SN Gene"). This strategic move aims to bolster the company's capabilities in genomics and expand its advanced diagnostic services.
SN Gene, incorporated in Gujarat on December 16, 2013, operates in the Diagnostics - Genomics sector. For the fiscal year 2026, SN Gene reported a turnover of ₹57.96 Crores, with turnovers of ₹53.36 Crores in FY2025 and ₹43.27 Crores in FY2024. The acquisition is not considered a related party transaction.
The total consideration for the 70% stake is up to ₹168 Crores in cash, with an additional performance-linked earn-out capped at ₹31.5 Crores. The transaction is expected to be completed by November 30, 2026. Post-acquisition, SN Gene will become a subsidiary of Dr. Lal Path Labs Limited.
What to do with a filing like this
Dr. Lal Path Labs Ltd. filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Lal Path Labs Ltd.. Read the original for the full detail.